The Gibco Adherent Kidney Media Panel includes four panel growth media and two panel production media.

Evaluate, optimize, and accelerate your time-to-market with the Adherent Kidney Media Panel

In the fast-paced world of vaccine development, finding the right cell culture media is crucial to optimizing productivity, improving product quality, and bringing vaccines to patients efficiently. However, relying on a trial-and-error approach can consume valuable time and resources. That's why a tailored media panel designed specifically for your needs can be a game-changer, accelerating and streamlining the process to help eliminate potential delays.

With the Gibco Adherent Kidney Media Panel, you can:

  • Compare diverse media options: Our panel enables you to simultaneously evaluate and compare multiple diverse media formulations side by side thus saving time and resources.
  • Identify key components for process improvement: By using our media panel, you can efficiently determine the critical components for optimal process performance. This knowledge empowers you to fine-tune your vaccine development workflow and can help you achieve higher titers in a shorter timeframe.
  • Discover the ideal formulation for your workflow: Gain access to six ready-to-use formulations, including four growth media and two production media. All options in the panel are serum-free, animal origin-free, and are either chemically defined or contain minimal quantities of peptones. This supports superior medium solutions that can enhance productivity and accelerate your time to market.

The Adherent Kidney Media Panel, specifically designed to support Vero cells in vaccine and viral vector applications. Our nutritionally diverse offering provides you with a range of high-quality media solutions. We understand the importance of superior medium formulations in maximizing productivity and minimizing time-to-market.

Chart illustrating the Adherent Kidney Media Panel supported multifold Vero cell titer growth in comparison to another supplier's production medium.

Figure 1. Adherent Kidney Media Panel Vero cell data compared to competitor. VSV titers with Growth Medium No. 3 and Production Medium No. 1 were strongest, with an average 10.6-fold TCID50 titer compared to another supplier’s media. Growth Medium No. 1 and Production Medium No. 1 also performed well, promoting a 5.0-fold relative titer compared to another supplier’s media. Compared to VP-SFM, Growth Medium No. 3 and Production Medium No. 1 supported a 7.0-fold relative titer, while Growth Medium No. 1 and Production Medium No. 1 supported a 3.3-fold relative titer.

Our scientists can provide technical support throughout the evaluation process and are available to provide process consultation, data analysis, and a summary report to expedite media optimization and cGMP manufacturing.

Take advantage of the Adherent Kidney Media Panel to unlock the potential for faster vaccine development, improved product quality, and accelerated delivery to patients. Contact us to learn more about how our media panel can revolutionize your vaccine development workflow.

Related Resources

 Application Note: Adherent Kidney Media Panel rapidly identifies serum-free growth and productivity media for enhanced viral vaccine production
 Article:  Q&A: Using media and feed panels during media development 
 Flyer:  Achieve exceptional performance with our new vaccine media panel

Bioprocessing resources

Access a targeted collection of scientific application notes, case studies, posters, white papers and more for bioprocessing:

Support

Events & Webinars

For Research Use Only. Not for use in diagnostic procedures.

For Research Use Only. Not for use in diagnostic procedures.